Production (Stage)
Inhibrx Biosciences, Inc.
INBX
$14.39
$0.473.38%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 1.69B | 1.66B | 1.61B | 1.60B | -280.46M |
| Total Depreciation and Amortization | 2.60M | 2.29M | 1.89M | 1.44M | 1.26M |
| Total Amortization of Deferred Charges | 2.60M | 3.31M | 4.55M | 5.79M | 6.14M |
| Total Other Non-Cash Items | -1.94B | -1.94B | -1.93B | -1.93B | 28.36M |
| Change in Net Operating Assets | 52.28M | 56.16M | 84.51M | 64.17M | 15.29M |
| Cash from Operations | -189.99M | -217.15M | -230.25M | -254.21M | -229.42M |
| Capital Expenditure | -1.50M | -2.60M | -6.02M | -6.59M | -5.69M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -1.50M | -2.60M | -6.02M | -6.59M | -5.69M |
| Total Debt Issued | 99.97M | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 71.68M | 110.41M | 111.49M | 311.51M | 241.04M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -41.56M | -41.43M | -41.66M | -41.79M | -27.32M |
| Cash from Financing | 130.09M | 68.97M | 69.83M | 269.72M | 213.73M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -61.40M | -150.77M | -166.44M | 8.93M | -21.38M |